Optimizing Sacituzumab Govitecan Tolerability in Early TNBC With Early Management: Antonio Llombart-Cussac, MD

In this interview from the American Society of Clinical Oncology (ASCO) Annual Meeting, Antonio Llombart-Cussac, MD, Medical Oncologist and Chairman of the Medical Oncology Service at University Hospital Arnau de Vilanova in Valencia, Spain, discusses his presentation on “Prevention of sacituzumab govitecan–related neutropenia and diarrhea in patients with triple-negative or HR+/HER2– advanced breast cancer.” He provides an overview of the study and its results and shares additional insights for making treatment tolerable for patients with advanced breast cancer.

About Dr. Llombart-Cussac

Antonio Llombart-Cussac, MD, Medical Oncologist and Chairman of the Medical Oncology Service at University Hospital Arnau de Vilanova in Valencia, Spain. He specializes in the treatment of breast cancer and coordinates a clinical unit integrated by pharmacologists, surgeons, pathologists, and biologists working with cytotoxic and molecular agents. His research focuses on translational clinical trials and correlative science in the management of ER-positive breast cancer.